Please assess the completion status of the following clinical trial:

Trial Title: GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent;~2. Age 18-75 years;~3. Patients diagnosed as advanced hepatocellular carcinoma (HCC) histopathologically or cytologically; Progression or intolerance after previous standard systemic therapy;~4. GPC3 is detected positive by immunohistochemistry (IHC);~5. Child-Pugh score ≤ 7;~6. At least one assessable tumor lesion;~7. ECOG score: 0-1;~8. Expected survival ≥ 3 months;~9. Clinical laboratory values meet screening visit criteria~Exclusion Criteria:~1. Previous CAR-T cell, TCR-T cell or other cell therapies or therapeutic tumor vaccination directed at any target;~2. Any previous GPC3 targeted therapy;~3. Prior antitumor therapy with insufficient washout period;~4. Brain metastases with central nervous system symptoms;~5. Pregnant or lactating women~6. HCV-Ab or/and HIV-Ab positive; active syphilis;~7. Severe underlying diseases~8. Any condition that, in the opinion of the investigator, will make the subject unsuitable for participation in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GPC3 Targeting CART Cells (Type: EXPERIMENTAL): Each subject will receive GPC3 Targeting CART cells

Based on this trial design, predict the completion outcome and termination type (if applicable).